2023 World Conference on Lung Cancer (Posters)-P2.09. JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC

P2.09. JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC - PDF(Abstract)

Back to course

Pdf Summary

The study presented in this abstract focused on the development and evaluation of a new drug called JIN-A04 for the treatment of metastatic non-small cell lung cancer (NSCLC) patients with HER2 exon20 insertion mutations. NSCLC is the most common type of lung cancer, and approximately 2-4% of NSCLC patients have HER2 mutations, with exon20 insertions being the most common. Unfortunately, a significant percentage of NSCLC patients develop brain metastases during the course of their illness, and treatment options for this subgroup are limited.<br /><br />The researchers conducted in vivo studies to evaluate the anti-tumor activity of JIN-A04 in both cell line derived tumor xenograft models and a brain metastases model. In the HER2GSP model, JIN-A04 demonstrated delayed tumor growth at all dose levels, with the highest dose significantly regressing tumor growth. Some of the dose groups even showed complete tumor eradication. Furthermore, in the NCI-H1781 model, JIN-A04 exhibited a significant and dose-dependent reduction in brain tumor volume after 3 weeks of administration.<br /><br />Based on these findings, the researchers concluded that JIN-A04 has the potential to be a promising drug candidate to address the unmet clinical need for NSCLC patients with HER2 exon20 insertion mutations. The drug showed robust activity against HER2 mutations and demonstrated effectiveness in reducing brain tumor volume. Therefore, JIN-A04 could provide a therapeutic opportunity for NSCLC patients with these specific mutations.<br /><br />This study highlights the importance of targeted therapies for specific genetic mutations in cancer treatment. By developing drugs that specifically target HER2 exon20 insertion mutations, researchers hope to improve outcomes for NSCLC patients and address the limitations of current treatment options.

Asset Subtitle

Mi Ra Yu

Meta Tag

Speaker Mi Ra Yu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

JIN-A04

metastatic non-small cell lung cancer

NSCLC

HER2 exon20 insertion mutations

lung cancer treatment

brain metastases

anti-tumor activity

tumor xenograft models

therapeutic opportunity

targeted therapies